Member Info for stt1

Even though they have around £12m, I think there will be a placing.

Bobat

"Slowly all pharma's are getting delisted"

Not always works though, does it?

Look at SLN, SUMM - both moved from AIM to US.

Still had placings/sp lower than when they moved.

Outside of pharmas.

Look at ad tech, trmr(now nexn, was blnx/rthm).

The dual listed, huge discounted placing when they IPO'ed.

Lots of brokers had significantly higher targets.

I warned of the ad tech bubble, history of placings etc.

The bubble burst and the sp crashed back down to around 230p.

https://www.lse.co.uk/profiles/stt1/?page=30

Then there's Byot, which delisted this week. Again, I warned of the lack of sales, competitors etc.

Several have crashed or sp lower.

1gw_ is the person to ask as he was invested in them and so has seen them crashing.

SpuddyMadrid,

That's history.

Look at the newsflow for PTX. There's newsflow in the public domain as to what has been happening with Silk Road Therapeutics, Soligenix's option agreement with Silk Road and phase 2a Behçet's Disease clinical study.

A year ago:

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

"The option agreement grants the Company the right to acquire a novel topical formulation of Pentoxifylline (PTX)"

https://www.prnewswire.com/news-releases/soligenix-enters-into-exclusive-option-agreement-with-silk-road-therapeutics-for-rights-to-topical-pentoxifylline-designed-to-treat-behcets-disease-301811424.html

Only a couple of months ago:

"Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024"

"The initiation of a Phase 2a clinical study in Behçet's Disease later this year will be another important milestone for our company and we look forward to working with the MAB to advance this program."

Comprised of internationally renowned rheumatologists with extensive experience in Behçet's Disease, the MAB will play an important advisory role in the conduct of the upcoming Phase 2a clinical study, as well as in the design of subsequent clinical studies and associated regulatory interactions with health authorities. "

https://www.prnewswire.com/news-releases/soligenix-announces-formation-of-behcets-disease-medical-advisory-board-302057074.html

Ricky,

I've seen other companies go down similar routes and only ended up raising more money and still below the IPO price they listed in the US.

Check the sp and newsflow for yourselves.

Look at SLN, SUMM..

Others ... ad tech dual listed Trmr, Nexn. IPO 800p only 3 years ago, now 230p.

Burton

" Shore Capital acted as Nominated Adviser and Joint Broker to Amryt Pharma plc during its listing on AIM in 2016, its strategic acquisitions and its dual listing on Nasdaq"

Question is why do they only refer to Amryt Pharma. Why not Fastnet Oil and Gas as well?. The same brokers were appointed only around 3 years earlier for their IPO, which had to resort to preserving cash and eventually reversed into Amryt.

Do they only mention Amryt Pharma because it was a success story? What about Fastnet Oil and Gas, NIL revenues at Polb or lack of revenue growth at HVO?

Fastnet Oil & Gas PLC : Change of Joint Broker

December 05, 2013 at 02:45 am EST

https://www.marketscreener.com/quote/stock/STERLING-GREEN-GROUP-PLC-4006748/news/Fastnet-Oil-Gas-PLC-Change-of-Joint-Broker-17592771/

"In 2015 the Board of Directors, including its Chairman Cathal Friel decided to shift Fastnet from an oil and gas company to a life sciences company. This decision flowed from the worldwide decline in oil and gas prices (from c. $120 a barrel to c. $30 a barrel) and the associated adverse sentiment towards small cap oil and gas concerns at the time.

The Company immediately conserved its cash, reducing overhead by 95%, thus creating a substantial cash shell with c. £15m in cash. In April 2015 Amryt Pharma completed the reverse takeover of Fastnet Oil & Gas."

https://www.raglancapital.ie/fastnet-oil-and-gas

Nathan,

"Mcap is 5ish mill usd. A capital raise for the silk road asset and some working cap to support activity alongside Corp activity"

They paying a nominal amount for a 12month option. Given they have around £12m cash, why would they need to raise money for it.

I think they need to raise money as they are clearly burning through nearly £4m a year.

As predicted.

Cash declining, admin costs increasing, revenues NIL

fy2021

revenue NIL

admin £2.031m

cash £20.949m

fy2022

revenue NIL (2021: NIL)

admin £3.06m (2021: £2.031m)

cash £16.193m (2021: £20.949m)

fy2023

revenue NIL (2022: NIL)

admin £3.376m (2022: £3.06m)

cash £12.171m (2022: £16.193m)

In the 3 years since IPO, cash down 2/3rds, admin costs up 75%, revenue remained at NIL.

I think they'll need a placing soon.

Read my posting history pages 8-9.

There was one poster, STTsBumbag, ramping and calling me a liar. See 'sales update' thread. I wonder why he disappeared? Wouldn't expect an apology from him, probably too ashamed to show himself.

Best to check everything posted on BBs.

https://www.lse.co.uk/ShareChat.html?ShareTicker=BYOT&share=Byotrol&page=9

Today was the last trading day before delisting.

That last 3.6m sell was at 0.001p and only returned £37!! It looked like a desperate last minute sell.

The same 3.6m trade would have cost around £365,000 in Aug 2020 at the highs. I was warning of the red flags, lack of sales, PI rampers churning trades throughout the past few years.

£360k to £37

The TU wasn't good. They still mention housing uncertainty and are firmly dependent on supportive market conditions. One of those supportive market conditions is mortgage interest rates.

"While we are mindful of ongoing market uncertainty and affordability challenges, it is pleasing to see continued market stability supported by good mortgage availability and sustained customer confidence"

"we are positioned for growth from 2025, assuming supportive market conditions."

"Outlook

We remain focused on prioritising value over volume, building a strong order book and positioning ourselves for growth from 2025, assuming supportive market conditions."

https://www.investegate.co.uk/announcement/rns/taylor-wimpey--tw./trading-statement/8150709

Several lenders have raised their mortgage interest rates:

https://www.bbc.co.uk/news/articles/c3g5jrl9yg4o

Latest AR available, fy2022, showed they had zero revenues, yet costs have increased.

Fy2023 ended 4 months ago and still no results. Last year they announced them on 30th March.

Where's the fy results?

Previously fy results were announced:

fy2021 03/03/22

fy2022 30/03/23

Rickylfc,

"There’s bound to be profit taking after the results"

Hindsight post. Why didn't you say so before the results were published.

"You never seem to respond when asked why you were warning of the dangers of Hvo at 10p and promoting the Tly business and its model at 28p??"

Very selective timeframe, isn't it?

Over the past few months, I've been posting HVO's company newsflow, facts and opinions based on those facts.

I've been saying the company is being talked up and maintaining that assertion, even when the sp was surging at 30p.

The fact is the Chairman dumped majority of his holding so he also obviously thought 28p was right price!!

I also was negative on HVO 2.5years when, as Orph, the sp was around 27p. They've hardly above that sp now after all this time, are they?

In terms of TLY, over the past few months, I've also been positive on them at 4p.

If you think HVO can go from 45p(3 years ago) to 10p to 28p then why do you think TLY or any other share can't?

If after all this time, the best argument against me is nothing better than trying to bully me into silence by posting on unrelated threads I contribute to tells me that I'm probably right in my views. If you could counter what I say with any kind of cogent, rational argument you would have by now.

The fact is the chairman/founder dumped majority of his holding in a discounted secondary placing.

The CEO has >7m options, awarded a year ago and now exercisable from a few months time.

Revenue/Order book growth has slowed significantly.

Some on here have no conviction in their investment and so pulling the wool over any gullible readers is their way of ramping the share.

Is it a coincidence that the following shares, which I also posted the company newsflow, facts and opinions on those facts, the red flags etc eventually crashed due to those red flags and posters from there also deramped TLY to pull the wool over gullible reader's eyes???.

Byot down 99.9% (now delisting), Trmr down 80%, rthm down 80%, Nano down 60%

H1-2024 revenue £55m

c40% held by institutions

No evidence of significant selling by institutionS between July 2023 and H1 end. Just small sells and hundreds of them to manipulate the shares.

Chairman has been buying.

Chairman is co-founder of Liberum and is director of other investment companies.

National contracts by NHS England

Provides their services in all 4 UK Nations AND Republic of Ireland. They have won contracts in RoI

They paid their fy dividend last Sept, so no evidence they were out of cash, All

AGM resolutions passed

Both Labour and Tories back the use of private providers by the NHS.

GE this year and both will be targeting improvements in the NHS.

Last 5 years:

fy period, revenue, cash, adj Ebitda

2019 £78m, £7.5m, £1.1m

2020 £105m, £8.9m, £4m

2021 £113M, £14.8m, £5m

2022 £127.4m, £15.3m, £6.2m

2023 £135.7m, £6.5m, £6.9m

H12024 £55.8m, £1.7m, £0.6m

Thorndon,

I post company newsflow, facts and opinions based on those facts, here and on the other shares.

Some don't like the company newsflow, facts and opinions based on facts that they think the best way to pull the wool over gullible reader's eyes is to deramp TLY.

It's far easier to manipulate the sp of an iliiquid company than counter the facts and opinions based on those facts.

It's not a coincidence that the other shares I've warned about have crashed due to the warnings I posted. Byot, down 99.9%. Trmr, down 80%. Rthm, down 80%. Nano, down 60%.

Best everyone reads the company newsflow, facts and form their own opinion.

StrictlyZinc

"Now that’s more like it!!"

How's the 1.2m compare to the 25m dumped by the Chairman/founder?

It's around 5% of the number dumped by him, isn't it?

Likewise, how does the 1.2m trade compare to the >7m options held by the CEO?

So if a 1.2m trade is 'big boys' have arrived, what is 25m dumped by the chairman or the 7m options held by the CEO, due to become exercisable in few months then?

Ricky,

The company newsflow and evidence is there for all to see and has been as predicted.

Shouldn't you be questioning why some rampers have already been proven to be completely wrong? Why not ask them to accept they were wrong?

There could be and likely to be more talking up of the company, as the CEO's huge options exercisable date gets closer, as per my assertions.

The newflow backs my assertions to date.

Fy results:

Nothing which wasn't expected, no rise post results.

Chairman dumped majority of his holding after shares talked up and before fy results.

Revenue/Order book growth rate has slowed significantly.

etc

etc

SZ,

"Same as last year really not a good move by the board."

As predicted, the nominal dividend hasn't made any difference.

I'm sure there'll be more hindsight opinions coming along agreeing with the bear points I've raised. My posts have been consistent.

Any more plausible throwaway comments or stories from the regulars here to pull the wool over PIs?

There should be a TU within days.

My thoughts.

given the sp is below nominal value, I fully expect some CA, which could include capital reorganisation or going private.

Positives:

Both Labour and Tories have endorsed the use of private companies to bring down waiting lists.

TLY provides it's services in all 4 UK Nations AND Republic of Ireland.

NHS have endorsed TLY services, which is evidenced by the national contracts awarded to them.

Over £55m revenues in H1, so expecting around £100m for fy.

c40% held by institutions and some increased. So TLY management are backed by significant holdings by IIs.

New Chairman was co-founder of Liberum and has been buying shares. He's obviously got contacts with IIs, who would back the company.

Consultants strike has ended

Wage inflation should have reduced considerably

Mcap only £9m.

Negatives:

Junior Doctors strike is still ongoing. That is the biggest problem facing the NHS.

Sp is below nominal value. Obviously the sp was manipulated lower by certain people to get to the position where TLY are forced to act.

Therefore, I expect CA, which could be capital restructuring as they did in 2019 or going private.

I, for one, have no problem if they go private because clearly there's huge demand for their services.

The company is clearly trusted by the NHS as evidenced by the contracts, especially the national contract awarded a few months ago.

If the company goes private and then they can concentrate or building the business without the distraction of muppets manipulating the sp. Then they can come back in 2-3 years time, multiple of today's low valuation. That would be a great bonus for retirement planning.